| INTRODUC TI ON
Glioblastoma (GBM) is one of the most devastating brain tumors with limited therapeutic options. The median survival is only 14 months even with multimodal therapies with surgery, radiation therapy and chemotherapy with temozolomide.
1,2 Glioblastoma patients may respond to temozolomide when MGMT promoter in the tumor cells is hypermethylated; however, the development of temozolomide resistance is inevitable. Temozolomide is ineffective when MGMT is hypomethylated. 3 Although a number of molecular targeting agents have been tested for their efficacy against glioblastoma in clinical trials, none has so far been proved to prolong overall survival of GBM patients. 4, 5 Development of a new effective drug for GBM is urgently needed. 2, 6 Among the numerous genetic mutations, [7] [8] [9] telomerase reverse transcriptase (TERT) promoter mutations, which are found in 60%-80% of glioblastomas, are the most common mutational events. 10, 11 TERT is a reverse transcriptase subunit of telomerase that maintains telomere length by utilizing TERC as an RNA subunit. 12 Telomere length is shortened at each cell division, and the cells undergo replicative senescence when telomeres attain a critical length. Most cancers, including gliomas, activate telomerase to evade this process. 13 The promoter mutations of TERT occur at 2 hotspots (−124C > T or −146C > T) in a mutually exclusive manner. Either of these mutations creates a de novo binding site for GABPA, which activates the promoter and upregulates TERT expression. 14, 15 The introduction of TERT promoter mutation in induced pluripotent stem cells abrogates telomerase silencing upon differentiation, and these cells overcome replicative senescence and infinitely multiply upon acquisition of proliferating mutations. 16 Thus, it appears that TERT promoter mutations are the most common driver oncogenic event in GBM, making it an attractive therapeutic target.
Telomerase targeting therapies have been a subject of interest for several decades. Although telomerase is activated in most cancer cells, the great majority of normal cells exhibit only a low level of telomerase, making it an ideal cancer-specific target. However, this strategy has not yet materialized in clinical settings. 17 Imetelstat, an antisense oligonucleotide that inhibits telomerase by binding to TERC, is the only telomerase-targeting drug that has been evaluated in phase II clinical trials of brain tumors. 18 Although telomerase inhibition was observed, no objective response of imetelstat was achieved in refractory pediatric brain tumors. 19 An inherent problem of targeting telomerase is that the inhibition of telomerase in a cancer cell already having elongated telomeres would not yield an immediate anti-proliferative effect. Telomerase inhibition may also lead to the activation of alternative lengthening of telomeres (ALT), a homologous recombination-based telomerase-independent telomere elongation mechanism, which would abrogate the effects of telomerase-targeting anticancer therapy. 17 Growing evidence indicates that TERT may have a telomerase-independent activity ("non-canonical function"). 20 One of the non-canonical functions of TERT is RNA-dependent RNA polymerase (RdRP) activity, which catalyzes the synthesis of an RNA strand complementary to a template RNA. 17, 21 Although TERT is well known as a reverse transcriptase, it has phylogenetic and structural similarities to viral RdRP, such as those present in hepatitis C virus, poliovirus and influenza virus. 17 In addition, TERT has been shown to be involved in the production of siRNA, 21 heterochromatin maintenance 22 and de novo synthesis of RNA. 23 Thus, TERT appears to function as an RdRP in mammals. Moreover, TERT forms a complex with Brahma-related gene 1 (BRG1) and nucleostemin (NS), which contributes to heterochromatin maintenance, mitotic progression 22 and maintenance of tumor-initiating cell phenotypes. 24 The suppression of TERT, BRG1 or NS disrupted heterochromatin formation and induced mitotic arrest. 22 These data suggest that the inhibition of RdRP activity instead of TERT activity may serve as a novel TERTtargeted anticancer strategy. 17 We have recently identified eribulin as a specific inhibitor of TERT-RdRP through drug screening. 25 Eribulin mesylate (Halaven, Eisai, Tokyo, Japan) is a fully synthetic analog of halichondrin B, a natural product isolated from marine sponge and originally developed as a microtubule inhibitor. 26 Eribulin is currently approved in more than 60 countries for the treatment of refractory breast cancers and liposarcomas. In a series of preliminary preclinical experiments, eribulin showed anticancer activities in diverse cancer cell lines, including a GBM cell line. [27] [28] [29] In this study, we investigated the efficacy of eribulin in inhibiting GBM cell proliferation in vitro and in vivo, as well as the pharmacokinetics of eribulin in a mouse harboring intracerebrally-transplanted human GBM cells. Our results showed that eribulin is active against GBM with TERT promoter mutations and penetrated mouse brain tumors. These data strongly suggest that eribulin can serve as an effective anticancer drug against GBM.
| MATERIAL S AND ME THODS

| Cell lines, vector, WST assay, pyrosequencing and ion proton analysis for targeted sequencing
Details of cell lines, vector, WST assay, pyrosequencing and ion proton analysis are described in a supporting document (Doc S1).
Genotypes of cell lines used in this study and ion proton analysis data are shown in the supporting information (Tables S1 and S2 ).
| Studies on brain tumor xenografts
Female BALB/c nu/nu athymic mice or SCID-beige (6-week to 8-week-old, Charles River Japan, Tokyo, Japan) were housed under specific pathogen-free conditions. To establish a mouse brain tumor xenograft, U87MG, U87MG-Fluc2, GSC23, GS-Y03 (1 × 10 5 cells in 2 μL PBS) or LN229 (5 × 10 5 cells in 2 μL PBS) cells were stereotactically inoculated into the right cerebral hemisphere of immunodeficient mice by using a Hamilton syringe and stereotactic micro-injector (Narishige, Tokyo, Japan). Saline (control) or eribulin (0.5 mg/kg) was administered to the mice 3 times per week (q2d × 3 per week). A 1-week treatment (3 injections) period was defined as 1 cycle, and an appropriate number of therapy cycles was applied to each study. All animal studies were conducted under the protocols approved by the Committee for Ethics of Animal Experimentation of National Cancer Center, and the experiments were carried out in accordance with the Guidelines for Animal Experiments. On the final day of saline or eribulin (day 20) administration, all the mice were killed, and the tumor specimens were harvested and quickly frozen in liquid nitrogen to measure RdRP activity as described below.
| Subcutaneous tumor xenografts
| Bioluminescence study
For in vivo bioluminescence study, eribulin or saline was injected into mice harboring U87MG-Fluc2 intracerebral tumors until the first mouse of the control group died. Bioluminescence signals were monitored on the same day of receiving injections, and the intensities of bioluminescence signals were statistically compared between the groups.
| Survival study
For in vivo survival study, eribulin or saline was intraperitoneally injected into mice harboring intracranial U87MG, LN229, GSC23 or GS-Y03 tumors. A total of 5 (U87MG), 9 (LN229), 2 (GSC23) or 3 (GS-Y03) cycles of treatment were applied to each group. The survival of mice was observed and analyzed using the Kaplan-Meier method.
| Pharmacokinetics study
Eribulin (0.5 mg/kg) was intravenously injected via the tail vein to mice bearing intracerebral U87MG xenografts. The mice were killed at several time points (15 minutes, and 1, 2, 4, 6 and 24 hours after injection; n = 3 for each time point). Normal brain tissue, brain tumor tissue and plasma were collected from each mouse at each time point and quickly frozen for further analysis. Plasma and tissue concentrations of eribulin were measured by using liquid chromatography-tandem mass spectrometry analysis (LC-MS/MS). The method is described in detail in a supporting document (Doc S1).
| Immunoprecipitation-immunoblotting
Immunoprecipitation-immunoblotting (IP-IB) was performed as previously described. 23 Molecular imaging of the distribution of eribulin in the brain tumor tissue was performed using matrix-assisted laser desorption/ ionization mass spectrometry imaging (MALDI-MSI). The method is described in detail in a supporting document (Doc S1). Briefly, frozen sections of 8 μm were thaw-mounted onto microscopic glass slides and were covered with 2,5-dihydroxybenzoic acid by using a sublimation apparatus (SVC-700TMSG/7PS80, SANYU Electron, Tokyo, Japan) and an ImagePrep (Bruker Daltonics, Tokyo, Japan) in 2 steps. 30 The distribution of eribulin in the brain tumor tissue was visualized at a high resolution using an atmospheric pressure imaging ion source (AP-SMALDI 10, TransMIT) coupled to a quadrupole orbitrap mass spectrometer (Q Exactive, Thermo Fisher Scientific).
| Immunoprecipitation-RdRP assay
The immunoprecipitation-RdRP (IP-RdRP) assay was performed as described previously with some modifications. 23 For all cell lines, 1 × 10 were captured by using a Typhoon FLA 7000 Phosphorimager and the signal intensities of the bands were quantified using ImageQuant TL software (GE Healthcare Japan).
| Liquid chromatography-tandem mass spectrometry analysis of eribulin concentration in brain tissue sections
The concentrations of eribulin in the targeted tissues/plasma were measured using a triple-quadrupole mass spectrometer (QTRAP 5500, AB SCIEX) coupled to a Shimadzu HPLC system (Nexera X2, Shimadzu). Chromatographic separation was performed on the Unison UK-C18 column (3 μm, 250 × 3 mm; Imtakt). The method is described in detail in a supporting document (Doc S1).
| Statistical analysis
The says were compared by log-rank test. A P-value <0.05 was considered significant. All analyses were performed using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA).
| RE SULTS
| Eribulin inhibits growth of glioblastoma cell lines with telomerase reverse transcriptase promoter mutations
The cytotoxic effect of eribulin on the TERT-mutated GBM cell lines U87MG, U251MG, U118MG and LN229 and patient-derived sphere-cultured cells GSC23 and GS-Y03 was examined in vitro using the WST assay ( Figure 1 ). All 6 cell lines had TERT promoter mutations (Table S1) 
| Eribulin significantly inhibited intracranial tumor growth
Next, we evaluated whether eribulin inhibited the growth of intracerebrally xenografted luciferase-expressing U87MG cells (U87MG-Fluc2) by using an in vivo imaging system. Transduction with a conventional replication-defective lentiviral vector 
| RdRP activity decreased in subcutaneous tumors after eribulin treatment
| D ISCUSS I ON
In this study, we showed that eribulin has an anticancer efficacy These results strongly suggested that eribulin may serve as a clinically applicable novel agent for glioblastoma.
In a previous preclinical study, glioblastoma was among the several cancer types that showed sensitivity to eribulin. 27, 31 However, glioblastoma was not considered a target for eribulin because the drug could not penetrate the blood-brain barrier (BBB). 31 This was most likely because eribulin is a substrate of Pglycoprotein (P-gp), an efflux transporter that plays an important role in elimination of drugs at the BBB. 32, 33 To explain the unex- 
36-38
The most intriguing finding in our study was that the concentration of eribulin in the U87MG brain xenograft remained high even 24 hours after the injection (91.7 ± 35.0 nM), although its concentration in the plasma decreased below the detectable level ( Figure 4 ).
MSI showed that eribulin was evenly distributed within the tumor tissue ( Figures 5 and 6 ). These data confirmed that eribulin penetrated the brain tumor tissue and remained in the tumor hours after the injection. A similar phenomenon was observed in subcutaneous U87MG xenograft, where eribulin concentration remained stable for 24 hours after intravenous injection, while it gradually decreased and became undetectable after 24 hours in the plasma, kidney and liver ( Figure S2 ). Furthermore, it was reported recently that eribulin quickly penetrated LOX human melanoma xenografts subcutaneously transplanted into mice. 39 The concentration of eribulin in the tumor was high and remained stable for at least 36 hours after single Eribulin was originally developed as a microtubule inhibitor. 43, 44 However, it has recently been shown to have specific inhibitory activity against TERT-RdRP as well. 25 TERT-RdRP appears to be involved in M-phase progression through the promotion of heterochromatin assembly and the maintenance of stem-cell property. 21, 22, 24 Inhibition of TERT using shRNA immediately induced mitotic arrest. 22 A previous study reported that the suppression of ovarian cancer cell growth by eribulin was dependent on the TERT status. 25 In the present study, we showed that TERT-RdRP activity in subcutaneous U87MG xenografts treated with eribulin decreased in a dose-dependent manner ( Figure 6 ). A similar tendency was observed in an intracerebral U87
MG xenograft model ( Figure S5 ), although the difference was not statistically significant, most likely because the mouse brain tumor specimen treated with eribulin was too small. These results suggested that eribulin may exert anticancer effect through its function as a TERTRdRP inhibitor in addition to microtubule inhibitor activity. Further investigation assessing the exact mechanism by which eribulin suppresses tumor cell growth is underway.
A few studies have been conducted to detect the biomarker of eribulin in breast cancer and liposarcoma; [45] [46] [47] however, no robust biomarker for eribulin mesylate confirmed in clinical settings has been identified yet. No paper has ever described molecular profiles of glioblastoma in association with eribulin treatment. In fact, although all TERT-mutated cells used in this study exhibited high sensitivity to eribulin, there were small differences in IC 50 (0.15-2.12 nmol/L) among these cell lines. However, no distinct genetic changes were observed among the 93 genes examined for mutations (Table S2) . We are currently conducting a multicenter, phase 2, investigator-initiated clinical trial using eribulin in patients with recurrent glioblastoma and surgical specimens are being collected for molecular analysis for biomarkers to predict response to eribulin.
In conclusion, we showed that eribulin exerted anticancer activity against glioblastoma in vitro and in vivo, thereby significantly prolonging survival of mice harboring intracerebral glioblastoma xenografts. Eribulin penetrated brain tumor tissues and remained at a high concentration for more than 24 hours after its administration. Molecular imaging confirmed that eribulin was evenly distributed within the brain tumor tissues. In addition to microtubule inhibition, TERT-RdRP inhibition may account for the highly efficient anti-GBM activity of eribulin. Our results thus suggested that eribulin may serve as an effective drug against GBM. Based on these data, an investigator-initiated registration-directed clinical trial to evaluate the safety and efficacy of eribulin in patients with recurrent GBM (UMIN000030359, https ://upload.umin.
ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recpt no=R0000 34631 ) has been initiated and is currently enrolling patients. Koichi Ichimura https://orcid.org/0000-0002-3851-2349
ACK N OWLED G M ENTS
